Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAINS: Bevacizumab vs Corticosteroids for Symptomatic Cerebral Radiation Necrosis
NCT06888817Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in Cerebral radiation necrosis (CRN) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical Efficacy Composite Score at 12 weeks. Started Jun 2025; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
Cerebral radiation necrosis (CRN)
Beyond the preview
Go deeper on NCT06888817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888817.